Aliana Guerrieri Gonzaga

Medicine & Life Sciences

1. Tamoxifen 100%
2. Breast Neoplasms 84%
3. Fenretinide 60%
4. Placebos 34%
5. Breast 27%
6. Insulin-Like Growth Factor I 27%
7. Biomarkers 27%
8. Chemoprevention 25%
9. Carcinoma, Intraductal, Noninfiltrating 24%
10. Neoplasms 19%
11. Cytochrome P-450 CYP2D6 17%
12. Insulin-Like Growth Factor Binding Protein 3 16%
13. Metformin 14%
14. Estradiol 13%
15. Breast Density 13%
16. Sex Hormone-Binding Globulin 12%
17. Virulence 11%
18. Raloxifene Hydrochloride 11%
19. Recurrence 11%
20. exemestane 11%
21. Conjugated (USP) Estrogens 11%
22. 4-hydroxy-N-desmethyltamoxifen 11%
23. Budesonide 11%
24. Breast Carcinoma In Situ 10%
25. Breast Diseases 10%
26. Confidence Intervals 10%
27. Retinoids 10%
28. Estrogen Receptors 9%
29. Hormones 9%
30. Adiponectin 9%
31. Genotype 8%
32. collagen type I trimeric cross-linked peptide 7%
33. Somatomedins 7%
34. Hormone Replacement Therapy 7%
35. Insulin Resistance 6%
36. C-Reactive Protein 6%
37. Estrogens 6%
38. Therapeutics 6%
39. Pharmaceutical Preparations 6%
40. Incidence 6%
41. Tumor Biomarkers 5%
42. tamoxifen N-oxide 5%
43. Clinical Trials 5%
44. Vitamin A 5%
45. Lung 5%